Hepatotoxicity with combination of vemurafenib and ipilimumab.

By Antoni Ribas, F. Hodi, M. Callahan, C. Konto, J. Wolchok. New England Journal of Medicine, 2013

697 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/63d15a3a859898f2240a97ca7994ee4c27cf3e22

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Interestingly, higher rates of AST/ALT elevation of ∼20% have been reported with single-agent anti-PD-1 therapy in HCC [8], with the anti-PD-1 and anti-CTLA-4 mAb combination [34], or when anti-CTLA-4 mAb were combined with targeted therapy or chemotherapy [70, 71].”
EASL Clinical Practice Guidelines: Drug-induced liver injury. (2019, background): “For other groups, such as TNFa antagonists or checkpoint inhibitors, an association with the underlying mode of action is much more evident.(350,354) In particular for antibiotics it has been speculated that the strong predominance of DILI caused by these agents could be related to their effects on ”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “However, it is likely that unexpected toxicities will be encountered, as, for example, when ipilimumab was coadministered with an inhibitor of B-raf (Ribas et al., 2013).”
Immune Checkpoint Blockade in Cancer Therapy. (2015, background): “and vemurafenib resulted in frequent transaminitis in a phase I study and is not clinically recommended.(94) The combination of ipili-”
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2015, background): “Interestingly, higher rates of AST/ALT elevation of ∼20% have been reported with single-agent anti-PD-1 therapy in HCC [8], with the anti-PD-1 and anti-CTLA-4 mAb combination [34], or when anti-CTLA-4 mAb were combined with targeted therapy or chemotherapy [70, 71].”
Cancer immunotherapy: the beginning of the end of cancer? (2016, result): “due to hepatotoxicity [111]; however, preliminary data from a combination trial of ipilimumab with the BRAF inhibitor dabrafenib indicate that this combination can be tolerable [112].”
Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “However, a clinical trial testing a BRAF inhibitor (vemurafenib) in combination with anti-CTLA-4 (ipilimumab) was terminated due to hepatotoxicity (Ribas et al., 2013).”